New AI-based Technologies in Nuclear Medicine

Recruiting now

Conditions studied: Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy

In brief

The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.

Key facts

Study ID

NCT07174089

Run by

Azienda USL Reggio Emilia - IRCCS

People needed

1500

Starts

2021-07-30

Expected to finish

2026-12-31

Last updated by the study team

2026-05-29

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients undergoing PET/CT scans or therapeutic treatments with radiopharmaceuticals labelled with alpha or beta emitting nuclides

You may not qualify if…

• patients whose clinical or psychological conditions do not allow for their involvement

Where it is running

• Azienda USL IRCCS di Reggio Emilia — Reggio Emilia, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.